Description
This product utilizes CD8+ T cells that have been engineered with our proprietary GeneCircuit technology to specifically target CD22 ( clone IRO24). We employs the AAV (SP6-GFP-IL-4-KpnI) vector components and the SynExpress system of the lncRNA Base Editing/Negative feedback for a robust and sustained response against cancers.
Host
Humanized
Target
CD22
Clone
IRO24
Species Reactivity
Human
Cell Source
Modified CD8+ T cells
Sensor Gene
GFP
Promoter
SP6
Effector Gene
IL-4
Insertion Sites
KpnI
Gene Modification
Base Editing
Modification Domain
lncRNA
Carrier Type
AAV
Transformation Accuracy
0.9
Cell Culture
Suspension Culture

For Research Use Only | Not For Clinical Use

Online Inquiry
Related Products
Copyright © 2025 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.